Clinical Trial Update: Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating recombinant birch pollen allergen rBet v1-FV for birch pollen allergy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Birch Pollen Allergy

Drugs mentioned

• rBet v1-FV (recombinant Bet v 1-FV allergen immunotherapy)

Snippet

Sponsor: Allergopharma GmbH & Co. KG | Conditions: Birch Pollen Allergy | Phase 2 | Status: COMPLETED